A spin-out from the Center for Vascular Biotherapeutics, Hydra Biosciences is a biopharmaceutical company developing molecular regeneration medicines, novel cardiovascular therapies and drugs targeting novel ion channels. Tapping the unharnessed power of the body to heal itself is one of the last frontiers of medicine. With the identification of many animal genomes, it is now possible to identify the genes and pathways that can unleash the regenerative power locked within the human body.

Commercial applications for Hydra’s molecular regeneration medicines include diseases of the heart, vasculature, retina, central nervous system, pancreas, skin, and joints. Hydra Biosciences is based in Cambridge, Massachusetts. (source: www.hydrabiosciences.com)

Company News

Hydra Biosciences was formed in July 2001 and raised $30 million in 2 rounds of funding. The company was founded in Cambridge, MA with plans for a campus in Utah. Due to legal and financial limitations, the Utah campus plans were abandoned. The company employs 28 people with an average salary of $80,000.

Highlights

• Molecular regeneration medicines
• Novel cardiovascular therapies
• Drugs targeting novel ion channels.

• 28 FTEs
• Average salary $80,000